

OncoTherapy Science, Inc.

June 25, 2020

Announcement of the press release from Keio University School of Medicine regarding the publication of immunotherapy for neurofibromatosis type 2 (NF2)

OncoTherapy Science, Inc. (President & CEO: Jae-Hyun Park; hereinafter, “OncoTherapy”) announces that one of our collaborators, a research group at Keio University School of Medicine has issued a press release announcing a publication of the article regarding immunotherapy for neurofibromatosis type 2 (NF2).

Researchers (Dr. Masahiro Toda et al.) at Keio University School of Medicine have conducted a clinical study for the treatment of NF2 patients. The efficacy and the safety data of this study based on the analysis for seven NF2 patients who received peptide vaccination has been published online in Nature Communication (December 17,2020).

For detail, please refer to Keio University website.

<https://www.keio.ac.jp/ja/press-releases/2020/6/24/28-69859/> (in Japanese)

The result of this study has been published online in Nature Communications.

<https://www.nature.com/articles/s41467-019-13640-1>

*CTL induction was investigated by OncoTherapy in the collaborative research with Keio University School of Medicine.

OncoTherapy has transferred the operation of the tumor immunology department, which carried out this joint research to a consolidated subsidiary company, Cancer Precision Medicine, Inc..